Whatever happened to AstraZeneca’s “smoke and mirrors” man, Richard Lawrence? You remember him. He was the one who, in 1997, wrote a memo about Seroquel that praised the company’s efforts to put a “positive spin” on “this cursed study,” and added: I am not 100% comfortable with this data being made publically available at the present time …...
Pharma Industry Archive
April 2009
The “information” document filed by federal prosecutors against Mary Holloway describes what appears to be a rogue sales unit inside Pfizer dedicated to selling the painkiller Bextra off-label and at unapproved doses. Holloway is believed to be a former Pfizer employee (see Peter Rost’s join-the-dots conclusion) although documents in the case never explicitly state it....
Gilead received some good news today with the results of a positive phase 3 study of its new high-blood pressure drug, darusentan. Combined with Gilead’s purchase of CV Therapeutics to gain the chronic angina drug Ranexa, this marks a new push into the cardio-vascular area for a company that has made its riches by dominating the HIV space. But before we get all giddy about a company that,...
We’re a little late, but here are the 10 weirdest drug stories that popped up onto BNET’s radar during March. They were all too small to write about, but too strange to ignore: Did GlaxoSmithKline unwittingly reveal that Wynnona Judd’s latest album has been heavily photoshopped? John Mack compares the pics side by side, and concludes that the shots she had taken for the Alli...
Elan CEO Kelly Martin earned roughly half last year what he earned in 2007, news which should please angry investor Jack Schuler, who wants new management at the company. According to RTE: Kelly Martin earned $830,496 last year, compared to $1.9m the year before. The report states this is because he waived his 2007 cash bonus which would have been paid last year in exchange for share options....
Wyeth has won a fifth of eight race discrimination lawsuits filed against it by black workers at the drug company’s Pearl River, N.Y., factory. The cases are best known for the alleged incident in which a supervisor announced that she was “the head n—- in charge” in front of a black employee. That supervisor later claimed she was just quoting Morgan Freeman in the movie...
The FDA has banned Boehringer Ingelheim and eight other drug companies from selling illegal, unapproved pain drugs. The drugs removed from the market include high concentrate morphine sulfate oral solutions, hydromorphone and oxycodone. The FDA: “Consumers have a right to expect that their drugs meet the FDA’s safety and effectiveness standards,” said Janet Woodcock, M.D.,...
Amylin has adopted a financial suicide pact which, in the company’s own words, may bankrupt the company if dissident investors Carl Icahn and Eastbourne Capital get a majority of directors elected at the May 27 shareholder meeting. The pact is described in a lawsuit brought by a San Antonio pension fund; the suit is supported by Eastbourne. (The suit is also a rare example of something...
- Study Showing Drug Ads Are Linked to Higher Prices Has Flaws
- Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Viagra Now Available Intravenously
- Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next?
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Why J&J's Stelara Launch Should Target Dermatologists First
- NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids
- Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
- Why Pfizer Wants Your Car-Sick Dog to Travel on Thanksgiving
- FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed
- The Business Conundrums of Trying to Prevent Cancer
- Will FDA Approve MannKind's Insulin Inhaler?
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
Subscribe to Pharma blog comments RSS 
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- The 10 Weirdest Drug Stories of the Month
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Archives
Recommended Sources
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.